An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation

作者:Blasi Annabel*; Beltran Joan; Pereira Arturo; Martinez Palli Graciela; Torrents Abiguei; Balust Jaume; Zavala Elizabeth; Taura Pilar; Garcia Valdecasas Juan Carlos
来源:Transfusion, 2012, 52(9): 1989-1998.
DOI:10.1111/j.1537-2995.2011.03526.x

摘要

BACKGROUND: Rotation thromboelastometry (TEM) has been proposed as a convenient alternative to standard coagulation tests in guiding the treatment of coagulopathy during orthotopic liver transplantation (OLT). This study was aimed at assessing the value of TEM in monitoring blood coagulation and guide transfusion support in OLT. STUDY DESIGN AND METHODS: Standard coagulation and TEM (EXTEM and FIBTEM) tests were performed at four preestablished intraoperative time points in 236 OLTs and prospectively recorded in a dedicated database together with the main operative and transfusion data. Transfusion thresholds were based on standard coagulation tests. Spearman's rank correlation (?), linear regression, and receiver operating characteristic curves were used when appropriate. RESULTS: EXTEM maximum clot firmness (MCFEXTEM) was the TEM variable that best correlated with the platelet (PLT) and fibrinogen levels (? = 0.62 and ? = 0.69, respectively). MCFFIBTEM correlated with fibrinogen level (? = 0.70). EXTEM clot amplitude at 10 minutes (A10EXTEM) was a good linear predictor of MCFEXTEM (R2 = 0.93). The cutoff values that best predicted the transfusion threshold for PLTs and fibrinogen were A10EXTEM = 35 mm and A10FIBTEM = 8 mm. At these values, the negative and positive predictive accuracies of TEM to predict the transfusion thresholds were 95 and 27%, respectively. CONCLUSION: A10EXTEM is an adequate TEM variable to guide therapeutic decisions during OLT. Patients with A10EXTEM of greater than 35 mm are unlikely to bleed because of coagulation deficiencies, but using A10EXTEM of not more than 35 mm as the sole transfusion criterion can lead to unnecessary utilization of PLTs and fibrinogen-rich products.

  • 出版日期2012-9